Q3FY 25: Metropolis Healthcare revenue up 11%

Metropolis Healthcare’s revenue grew by 11% on a YoY basis in Q3FY 25.

In its communiqué to BSE and NSE, the company gave its update on the Q3FY 25 results.

“Revenue growth was driven by patient volume growth, test volume growth, and change in product mix coupled with realization benefits. B2C revenues grew at approx. 15% on a Y-o-Y basis on account of industry-leading testing capabilities and strong brand appeal among end consumers. Company is considering a price increase in the B2C in some cities in India effective Q4FY25,” the company said.

Metropolis noted that the company is debt-free and has cash reserves of approximately Rs 200 crore as of December 31, 2024.

In Q3FY25, the company recorded double-digit revenue growth during a period that is generally a seasonally lean period for diagnostic companies, particularly those operating in the West and South regions. Additionally, the company achieved a modest year-on-year increase in margins despite seasonally lower revenue growth and constrained operating leverage.

The company reported mid-teens revenue growth in its B2C segment and low double-digit growth in its B2B segment. However, overall revenue growth was affected by a decline in the institutional business, which is not a primary focus for the Company.

Truhealth wellness and bundling segment has performed exceptionally well, emerging as the fastest-growing category with an impressive growth rate of approximately 25% for Q3FY25, the company said.
MB Bureau